Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Pamela Roberto, PhD
Advertisement
Articles by Pamela Roberto, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Childhood Vaccine Order: What It Means for Parents and Payers
2
Senate Unveils Sweeping Bill to Reform 340B Drug Program
3
Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation
4
FDA Proposes GRAS Rule, Advances Ultra-Processed Food Definition
5